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The ubiquitin-like SUMO system controls cellular key functions, and several lines of evidence point to a critical role of
SUMO for mitotic progression. However, in mammalian cells mitotic substrates of sumoylation and the regulatory
components involved are not well defined. Here, we identify Borealin, a component of the chromosomal passenger
complex (CPC), as a mitotic target of SUMO. The CPC, which additionally comprises INCENP, Survivin, and Aurora B,
regulates key mitotic events, including chromosome congression, the spindle assembly checkpoint, and cytokinesis. We
show that Borealin is preferentially modified by SUMO2/3 and demonstrate that the modification is dynamically
regulated during mitotic progression, peaking in early mitosis. Intriguingly, the SUMO ligase RanBP2 interacts with the
CPC, stimulates SUMO modification of Borealin in vitro, and is required for its modification in vivo. Moreover, the
SUMO isopeptidase SENP3 is a specific interaction partner of Borealin and catalyzes the removal of SUMO2/3 from
Borealin. These data thus delineate a mitotic SUMO2/3 conjugation–deconjugation cycle of Borealin and further assign
a regulatory function of RanBP2 and SENP3 in the mitotic SUMO pathway.
INTRODUCTION
The ubiquitin-like SUMO system is involved in the regula-
tion of several cellular key processes, including transcrip-
tional control, DNA repair, and recombination (Gill, 2004;
Muller et al., 2004; Hay, 2005). The unifying theme of SUMO
function in these pathways seems to be the SUMO-depen-
dent regulation of specific protein–protein interactions
(Geiss-Friedlander and Melchior, 2007). In humans, at least
three SUMO forms (SUMO1, 2, and 3) are expressed.
SUMO2 and SUMO3 are highly related proteins sharing an
identity of 97% (we therefore refer to them as SUMO2/3),
whereas SUMO1 shares 43% identity with SUMO2/3. The
covalent attachment of SUMO to a lysine residue within a
target protein is catalyzed by an enzymatic cascade involv-
ing the E1-activating enzyme (Aos1/Uba2), the E2-conjugat-
ing enzyme Ubc9, and, at least in some cases, additional E3
ligases, such as protein inhibitor of activated signal trans-
ducers and activators of transcription (PIAS) family mem-
bers, human Polycomb protein 2 (hPc2), and Ran binding
protein 2 (RanBP2) (Pichler et al., 2002; Kagey et al., 2003;
Schmidt and Muller, 2003). Although PIAS-mediated sumo-
ylation has been observed on many substrates, only recently a
first in vivo substrate for RanBP2-dependent sumoylation has
been identified (Dawlaty et al., 2008).
Importantly, SUMO modification is a highly dynamic and
reversible process. The abundance of a given SUMO-
conjugate is dynamically regulated by a balance between
SUMO modification mediated by the E1, E2, and E3 en-
zymes and demodification, which is governed by SUMO-
specific isopeptidases of the ubiquitin-like protease (Ulp/
SENP) family (Hay, 2007; Mukhopadhyay and Dasso, 2007).
In humans, six members of this family, termed SENP1-3 and
SENP5-7, have been identified so far. A characteristic feature
of distinct SENPs is their distribution to specific subcellular
regions, indicating that their activity is spatially regulated.
Data from genetic studies in yeast indicate that a balanced
equilibrium of SUMO conjugation and deconjugation is crit-
ical for mitotic events, including mitotic entry and proper
chromosome segregation during anaphase (Watts, 2007;
Dasso, 2008). Recent work has also revealed the importance
of sumoylation for mitotic progression in mammalian cells
and has delineated a critical role of SUMO in kinetochore/
centromere function (Di Bacco et al., 2006; Dawlaty et al.,
2008; Zhang et al., 2008). However, in higher eukaryotes,
only few mitotic targets of SUMO and regulatory compo-
nents of the SUMO pathway are known.
Progression through mitosis is tightly coordinated by mi-
totic kinases. The kinase Aurora B is important for key
mitotic events, including chromosome congression, the spin-
dle assembly checkpoint, and cytokinesis (Meraldi et al.,
2004; Giet et al., 2005; Ruchaud et al., 2007). Aurora B is part
of a multiprotein complex, termed the chromosomal passen-
ger complex (CPC), which additionally comprises INCENP,
Survivin, and Borealin (also known as DasraB; Sampath et
al., 2004). The CPC binds to the centromere in prometaphase
and metaphase, relocates to the central spindle at the onset
of anaphase, and accumulates at the midbody during telo-
phase and cytokinesis. Accordingly, phosphorylation targets
of Aurora B have been identified at each of these sites
(Zeitlin et al., 2001; Andrews et al., 2004; Ohi et al., 2004; Neef
et al., 2006). The components of the CPC are physically and
functionally interdependent in that depletion of any one
subunit by RNA interference abolishes correct localization of
the others and inhibits proper CPC function (Honda et al.,
2003; Gassmann et al., 2004; Jeyaprakash et al., 2007).
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Recent work has underscored the importance of post-
translational modification for proper activity and accurate
spatiotemporal control of the CPC. For example, phosphor-
ylation of Borealin by Mps1 is crucial for Aurora B activity
and chromosome alignment (Jelluma et al., 2008). Moreover,
the ubiquitin system regulates the dynamic association of
passenger proteins with the centromere and chromatin
(Vong et al., 2005; Ramadan et al., 2007).
Here, we report that Borealin is dynamically modified by
SUMO2/3 during mitosis. We identify RanBP2 as an essen-
tial regulator of the conjugation process and SENP3 as the
SUMO protease-catalyzing deconjugation.
MATERIALS AND METHODS
Cell Culture, Transfection and Western Blotting
HeLaS3 or COS-7 cells were grown under standard conditions. Plasmid
transfections were performed using FuGENE 6 reagent (Roche Diagnostics,
Mannheim, Germany). The following antibodies were used for Western blot-
ting: anti-SUMO1 (clone 21C7; Zymed Laboratories, South San Francisco,
CA), anti-SUMO2/3 (clone 1E7, MBL, Woburn, MA), anti-ubiquitin (Epitom-
ics, Burlingame, CA), anti-PIAS2 (clone 116, Sigma Chemie, Deisenhofen,
Germany), anti-RanBP2 (gift of Frauke Melchior, University of Go¨ttingen,
Go¨ttingen, Germany), anti-Ubc9 (clone 50; BD Biosciences, San Jose, CA),
anti-SENP5 (gift of Ed Yeh, MD Anderson Cancer Center, Houston, TX),
anti-cyclin B1 (BIOMOL Research Laboratories, Plymouth Meeting, PA), anti-
Eg5 (Blangy et al., 1995), anti-PML (rabbit polyclonal; Millipore Bioscience
Research Reagents, Temecula, CA), anti-topoisomerase II (clone 1C5; Assay
Designs, Ann Arbor, MI), anti-hemagglutinin (HA) (clone 16B12; Covance
Research Products, Princeton, NJ), goat anti-mouse immunoglobulin G (IgG)
(Invitrogen, Carlsbad, CA). Anti-SENP3 antibodies have been described pre-
viously (Haindl et al., 2008). All other antibodies have been described previ-
ously (Klein et al., 2006).
Cloning and Mutagenesis
The cDNAs for chromosomal passenger proteins have been described previ-
ously (Klein et al., 2006) and were cloned into pcDNA3.1 (Invitrogen) encod-
ing a 3xmyc tag. For His-tagging and HA-tagging, Borealin was cloned into
pcDNA3.1 encoding a 6xHis-tag or a HA-tag, respectively. Myc-PARP1 and
myc-RanBP2FG were cloned into pCI (Invitrogen). SUMO constructs have
been cloned into pSG5 (Stratagene, La Jolla, CA) for His-tagging or pcDNA3.1
for HA-tagging. SENPs were cloned into pCI (Invitrogen) for FLAG-tagging.
Site-directed mutagenesis was carried out using the QuickChange mutagen-
esis kit (Stratagene).
RNA Interference (RNAi) Sequences
mRNAs were targeted as follows: Ubc9, 5-GCAGAGGCCUACACGAUUU
dTdT-3; and Eg5, 5-CUAGAUGCCUUUCUCAGUAdTdT-3. Small interfering
RNA (siRNA) oligonucleotides for RanBP2, PIAS2 (targeting the  and  iso-
forms), Borealin, SENP3, and SENP5 have been described previously (Joseph et
al., 2004; Yang and Sharrocks, 2005; Klein et al., 2006, Haindl et al., 2008).
Yeast Two-Hybrid Assay
cDNAs encoding the respective prey or bait proteins were cloned in frame
with the GAL activation domain of pACT2 or pGAD vectors or the GAL
binding domain of pFBT9 or pGBD vectors and tested for self-activation.
Directed yeast two-hybrid assays were performed as described previously
(Klein et al., 2006).
In Vitro Sumoylation and Desumoylation
Proteins were generated by in vitro transcription/translation in the presence
of 35S-labeled methionine using the TNT Quick Coupled T7 kit (Promega,
Madison, WI). Sumoylation was carried out using the Sumoylation control kit
(LAE Biotech, Rockville, MD). In experiments using recombinant RanBP2FG
(BIOMOL Research Laboratories) the amount of Aos1/Uba2 and Ubc9 was
reduced to 100 and 70 nM, respectively. In vitro demodification assays were
done as described previously (Haindl et al., 2008). In vitro processing activity
of SENP3 and SENP5 was assayed on N-terminal FLAG-tagged SUMO2
full-length, C-terminal fused to the HA-tag (FLAG-SUMO2-HA).
In Vivo Sumoylation
After transfection of respective constructs, HeLaS3 or COS-7 cells were incu-
bated for 48 h and nickel-nitrilotriacetic acid (Ni-NTA) precipitations were
done as described previously (Muller et al., 2000). Where indicated, siRNA
duplexes were transfected simultaneously.
Cell Cycle-dependent Sumoylation
HeLaS3 cells were transfected with His-tagged Borealin and incubated for
30 h. Thymidine or taxol was added at a concentration of 2 mM and 1 M,
respectively, and cells were incubated for an additional 16 h. Taxol-arrested
cells were released into 10 M MG132 (Calbiochem, San Diego, CA) for 1 h to
obtain metaphase cells. To harvest anaphase/telophase cells, corresponding
cell populations were released from this block for 25 and 50 min, respectively.
Cell lysates and Ni-NTA pull-downs were performed as described above. For
the experiment in Supplemental Figure 1, cells where arrested by thymidine
or taxol as outlined above, and MG132 was added at 10 M for 2 h before
lysate preparation.
Coimmunoprecipitation
To immunoprecipitate endogenous Borealin, HeLaS3 cells were harvested by
mitotic shake-off after 16-h taxol treatment (1 M). To test for a Borealin-
SENP3 interaction, COS-7 cells were simultaneously transfected with myc-
tagged Borealin and FLAG-tagged SENP3 constructs and immunoprecipita-
tions were done as described previously (Klein et al., 2006). To demonstrate
endogenous sumoylation HeLaS3 cells were arrested by a 16 h taxol treatment
before harvesting. Lysates were prepared in buffer A (50 mM Tris-HCl, pH
7.5, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM
dithiothreitol, 10 mM CaCl2, 200 U/ml micrococcal nuclease [MBI Fermentas,
Hanover, MD], 10 mM N-ethyl maleimide [Pierce Chemical, Rockford, IL],
and protease inhibitors [Complete; Roche Diagnostics, Basel, Switzerland])
and subjected to immunoprecipitation with 10 g of SUMO2/3 antibody or
control mouse IgG.
Immunofluorescence Microscopy
Immunofluorescence was performed as described previously (Baumann et al.,
2007) with the following primary antibodies: PRC1 (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), FLAG-M2 (Sigma Chemie), RanBP2 (a kind gift of
Frauke Melchior), HA (clone 16B12; Covance Research Products), and
CENP-E (Santa Cruz Biotechnology). All other antibodies have been de-
scribed previously (Klein et al., 2006). Secondary antibodies were Cy2/Cy3-
conjugated donkey antibodies (Dianova, Hamburg, Germany).
Gene Expression Analysis of RanBP2 and
Phosphorylation of SENP3
Analysis of mRNA levels by quantitative reverse transcription-polymerase
chain (RT-PCR) reaction were done as described previously (Graser et al.,
2007). For normalization, expression of -glucuronidase was measured. To
monitor RanBP2 protein level, lysates were prepared from asynchronous
growing HeLaS3 cells or HeLaS3 cells released from a double thymidine block
into nocodazole (0-min time point). To determine protein levels at later stages
of mitosis, cells were released from the nocodazole block for different time
points. To study phosphorylation of SENP3, lysates were prepared from
asynchronous growing HeLaS3 cells or HeLaS3 cells arrested by nocodazole
or thymidine. For dephosphorylation the lysates were treated with 500 U of 
phosphatase (New England Biolabs, Ispwich, MA) or for control reactions 
phosphatase together with phosphatase inhibitors (10 mM NaF and 1 mM
sodium orthovanadate).
RESULTS
The CPC Subunit Borealin Is Covalently Modified by
SUMO
To obtain insight into the role of the Borealin subunit of the
CPC, we screened a yeast two-hybrid HeLa cDNA library
with full-length Borealin as the bait and identified two com-
ponents of the ubiquitin-like SUMO modification system,
the E2-conjugating enzyme Ubc9, and the modifier SUMO1
as interaction partners of Borealin. Directed yeast two-hy-
brid assays confirmed these interactions and additionally
revealed an interaction of Borealin with SUMO2 (Figure 1, A
and B). The other known members of the CPC—INCENP,
Aurora B, and Survivin—did not bind Ubc9 or SUMO forms
(Figure 1A; data not shown). The binding of Borealin to both
SUMO paralogues was dependent on the integrity of their
C-terminal double-glycine motif, which is essential for con-
jugation, suggesting that SUMO is covalently attached to
Borealin (Figure 1B, bottom two panels).
To test this hypothesis, we used a reconstituted in vitro
SUMO modification system. 35S-labeled myc-tagged Borea-
lin, generated by in vitro transcription/translation, was in-
cubated with recombinant components of the sumoylation
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machinery, i.e., the E1 activating enzyme Aos1/Uba2, the E2
conjugating enzyme Ubc9, and either SUMO1 or SUMO2
in the presence of ATP. In the control reaction, which lacked
the E1 enzyme, a single major Borealin band, migrating at
the predicted size of 42 kDa was detected (Figure 1C). In
contrast, addition of the E1 enzyme to the reaction resulted
in the formation of at least three distinct higher-molecular-
weight Borealin conjugates both with SUMO1 (Figure 1C)
and SUMO2 (Figure 1D). The major conjugates migrated at
50, 64, and 75 kDa, being consistent with the attach-
ment of up to three SUMO moieties to Borealin. In line with
the finding that only Borealin but no other chromosomal
passenger protein interacted with SUMO pathway compo-
nents in the yeast two-hybrid assay, neither Survivin, nor
Aurora B and INCENP were significantly modified by
SUMO (Figure 1C).
To examine whether SUMO paralogues can also modify
Borealin in vivo, a myc-tagged construct of Borealin was
coexpressed with either HA or His-tagged constructs of
SUMO1 or SUMO2. His-SUMO-conjugates were affinity pu-
rified under denaturing conditions on Ni-NTA beads. Con-
sistent with the result obtained in the in vitro sumoylation
assay, Western blotting with an anti-myc antibody detected
three SUMO-Borealin species in His-SUMO1 and His-
SUMO2 pull-downs (Figure 2A). Survivin, a direct binding
partner of Borealin within the CPC (Gassmann et al., 2004;
Klein et al., 2006), was neither conjugated to SUMO1 nor
SUMO2 under these conditions (Figure 2B). SUMO mutants
(SUMO1K16R and SUMO2K11R), where potential residues for
chain formation were mutated (Hay, 2005), generated an
identical pattern of SUMO–Borealin conjugates (Figure 2C),
arguing for sumoylation of distinct lysine residues within
Borealin. To determine whether Borealin is preferentially
modified by either SUMO1 or SUMO2/3, when these mod-
ifiers are expressed at their endogenous levels, a His-tagged
Borealin construct or an empty His-vector control was ex-
pressed in HeLa cells and proteins were purified on Ni-NTA
beads under denaturing conditions from mitotic cell lysates.
Western blotting with an anti-Borealin antibody allowed for
the detection of higher-molecular-weight species (Figure
2D), reminiscent of the Borealin–SUMO conjugates de-
scribed above. When blotted with SUMO2/3-specific anti-
bodies, at least two bands were identified as SUMO2/3
conjugates. By contrast, antibodies directed against SUMO1
or ubiquitin did not specifically detect these bands. To test
modification of endogenous Borealin by SUMO2/3, total
cellular SUMO2/3-conjugates from mitotic cell lysates cells
were immunoprecipitated by anti-SUMO2/3 antibodies
Figure 1. Borealin interacts with components of the SUMO system
and is modified by SUMO in vitro. (A and B) Interaction of Borealin
with Ubc9 (A) and the conjugatable forms of SUMO1 and SUMO2
(B, top two rows), but not the unconjugatable forms (SUMOGA) (B,
bottom two rows) in directed yeast two-hybrid assays. LW indi-
cates plates lacking leucine and tryptophane, whereas QDO indi-
cates plates lacking leucine, tryptophane, histidine, and adenine. (C
and D) Borealin is modified by SUMO in vitro. 35S-Labeled CPC
subunits, generated by in vitro transcription/translation, were in-
cubated with recombinant E1, E2, and either SUMO1 (C) or SUMO2
(D) in the presence of ATP. In control reactions, the E1 enzyme was
omitted. SUMO–Borealin conjugates are indicated by arrows.
Figure 2. Borealin is modified by SUMO in vivo and is preferen-
tially targeted by SUMO2/3. (A) Myc-tagged Borealin and HA- or
His-tagged versions of SUMO1 or SUMO2, respectively, were coex-
pressed in COS-7 cells. His-SUMO conjugates were recovered on
Ni-NTA beads and subjected to Western blotting by using anti-myc
antibody. (B) Myc-Survivin was tested for sumoylation as described
in A. (C) Myc-tagged Borealin and either wild-type (SUMO1wt,
SUMO2wt) or mutant versions of His-tagged SUMO forms
(SUMO1K16R, SUMO2K11R) were coexpressed in COS-7 cells and
analyzed as described in A. (D) Borealin is modified by endogenous
SUMO2/3, but not SUMO1. HeLa cells expressing His-tagged Bo-
realin were arrested in prometaphase by taxol treatment for 16 h.
His-Borealin was recovered on Ni-NTA beads, and immunoblotting
was performed with anti-Borealin, anti-SUMO1, anti-SUMO2/3, or
anti-ubiquitin antibodies. The Borealin-reactive bands at 45 kDa
(asterisk) are interpreted as a Borealin–SUMO2/3 degradation
product. (E) Endogenous Borealin is conjugated to SUMO2/3. Im-
munoprecipitations were performed with anti-SUMO2/3 or control
IgGs from taxol-arrested HeLa cells and probed by Western blotting
with the indicated antibodies.
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(Figure 2E). We validated the experimental setup by moni-
toring sumoylation of topoisomerase II (Azuma et al., 2003,
2005; Zhang et al., 2008), a SUMO2/3 substrate that is spe-
cifically conjugated in early mitosis, and PML, a SUMO2/3
substrate that is unmodified at this stage (Everett et al., 1999).
Consistently, we detected topoisomerase II–SUMO2/3
conjugates, but no PML–SUMO2/3 forms in the mitotic
SUMO2/3 precipitates. Importantly, anti-Borealin–reactive
forms migrating at 50 and 64 kDa were specifically enriched
in the anti-SUMO2/3 pull-down fraction. The amount of
Borealin–SUMO2/3 conjugates was comparable to the
amount of topoisomerase II–SUMO2/3 species. In sum-
mary, these data define the CPC subunit Borealin as a mi-
totic substrate for sumoylation and indicate that it is prefer-
entially modified by SUMO2/3.
The SUMO E3 Ligase RanBP2 Is Essential for
Sumoylation of Borealin
To address whether sumoylation of Borealin is cell cycle
regulated, HeLa cells expressing His-tagged Borealin were
harvested at different stages of the cell cycle and Borealin-
SUMO2/3 conjugates were purified on Ni-NTA beads (Fig-
ure 3A and Supplemental Figure 1). In G1-arrested cells, the
level of Borealin-SUMO2/3 conjugates was low (Figure 3A,
lane 5). Strikingly, the amount was strongly increased in
metaphase-arrested cells (Figure 3A, lane 6 and Supplemen-
tal Figure 1), before the conjugates were progressively lost as
cells entered anaphase (Figure 3A, lane 7 and 8). Thus, we
conclude that sumoylation of Borealin is dynamically regu-
lated during cell cycle progression with a peak in early
mitosis.
This notion led us to search for regulatory components
that control the dynamic modification of Borealin. To this
end, candidate SUMO E3 ligases, notably, PIAS family
members RanBP2 and hPC2, were analyzed for their abil-
ity to interact with Borealin in a yeast two-hybrid system.
Binding of Borealin was observed to the  and  splice
variants of PIAS2 and the catalytically active fragment of
RanBP2 (RanBP2FG) (Pichler et al., 2002) (Supplemental
Figure 2A). To test for these interactions in mammalian cells,
endogenous Borealin was immunoprecipitated from mitotic
HeLa cells (Figure 3B). Importantly, RanBP2, but not PIAS2
isoforms, were specifically detected in anti-Borealin precip-
itates. Attesting to the specificity of this interaction, coim-
munoprecipitation was also observed for Aurora B, but not
for Hec1, another component of the centromere/kinetochore
region. This indicates that RanBP2 can bind to the CPC and
thus represents a potential SUMO E3 ligase for Borealin. In
line with this assumption, RanBP2 was shown previously to
localize to the centromere/kinetochore region and the mi-
totic spindle (Yokoyama et al., 1995; Joseph et al., 2002, 2004).
To address a putative SUMO E3 ligase function of RanBP2
toward Borealin, recombinant RanBP2FG was added to an
in vitro sumoylation reaction on Borealin, which was per-
formed under limiting Ubc9 concentrations (70 nM). Under
these conditions, basal E1-E2–mediated sumoylation of Bo-
realin was weak (Figure 3C, top, lane 2), but addition of
RanBP2FG in a concentration range of 5 to 50 nM enhanced
the formation of the three Borealin–SUMO conjugates (Fig-
ure 3C, lanes 4 and 5), whereas it did not stimulate sumo-
ylation of the control substrate p53 (Figure 3C, bottom). In
agreement with previous data (Pichler et al., 2002), higher
concentrations of RanBP2 (500 nM) exert an inhibitory effect
on sumoylation (Figure 3C, top, lane 3), probably reflecting
a competitive automodification of RanBP2.
To further analyze the role of RanBP2 in the conjugation of
SUMO to Borealin in vivo, cells expressing myc-tagged Bo-
realin and His-SUMO2 were depleted of RanBP2 and control
proteins by small interfering RNA (siRNA) (Figure 3D).
Sumoylation of Borealin was monitored by Ni-NTA pull-
down of His-SUMO2 conjugates followed by anti-myc im-
munoblotting. Remarkably, depletion of RanBP2 resulted in
an almost complete loss of sumoylation and reduced the
level of Borealin–SUMO conjugates to almost the same ex-
tent as knockdown of the essential E2 enzyme Ubc9. In
contrast, Borealin sumoylation was unaltered in cells de-
pleted of the  and  forms of PIAS2. Noteworthy, depletion
of RanBP2 did not affect the level of total SUMO2/3-conju-
Figure 3. Sumoylation of Borealin is cell cycle regulated and re-
quires RanBP2. (A) Sumoylation of Borealin is cell cycle regulated.
HeLa cells expressing His-Borealin were arrested in G1 (lane 1),
metaphase (lane 2), or allowed to enter anaphase (lanes 3 and 4).
His-Borealin and His-Borealin-conjugates were detected by Western
blotting with anti-Borealin and anti-SUMO2/3 antibodies (lane
5– 8). Bands marked by asterisk are interpreted as Borealin–
SUMO2/3 degradation products. The mitotic status was assayed by
monitoring Cyclin B1 levels. (B) RanBP2 binds to the CPC. Immu-
noprecipitations were performed with rabbit anti-Borealin antibod-
ies or preimmune serum from taxol-arrested HeLa cells and probed
by Western blotting with the indicated antibodies. The anti-PIAS2
antibody is directed against the  and  isoforms. Asterisk denotes
an anti-PIAS2 cross-reactive band. (C) RanBP2 stimulates sumoyla-
tion of Borealin in vitro. 35S-labeled Borealin or p53, generated by in
vitro transcription/translation, were subjected to an in vitro sumoy-
lation assay under limiting E2 concentrations. RanBP2FG was
added at a concentration of 500 ng (lane 3), 50 ng (lane 4), and 5 ng
(lane 5). SUMO conjugates are indicated by arrows. (D) RanBP2 is
required for sumoylation of Borealin in vivo. Myc-tagged Borealin
and His-SUMO2 were coexpressed in HeLa cells treated with
siRNA oligonucleotides directed against indicated proteins. Deple-
tion was verified by Western blotting. The siRNA directed against
PIAS2 targets the  and  isoform (Yang et al., 2005). The asterisk in
the anti-PIAS2 Western blot denotes a cross-reactive band. His–
SUMO2 conjugates were recovered on Ni-NTA beads, and Western
blotting was performed with anti-myc antibodies.
SUMO 2/3 Conjugation-Deconjugation of Borealin
Vol. 20, January 1, 2009 413
gates (Supplemental Figure 3A) or sumoylation of the
unrelated control substrate poly(ADP-ribose) polymerase
(PARP)1 (Gocke et al., 2005) (Supplemental Figure 3B), indi-
cating that RanBP2 does act on specific SUMO target pro-
teins. Furthermore, depletion of Eg5, which, similar to the
knockdown of RanBP2 (Joseph et al., 2004), leads to a pro-
metaphase-like arrest (Blangy et al., 1995), did not influence
sumoylation of Borealin.
To address whether the observed loss of Borealin sumoy-
lation can be assigned to the enzymatic activity of RanBP2,
HeLa cells were depleted of endogenous RanBP2 and com-
plemented with either wild-type or catalytically inactive
RanBP2FG (Dawlaty et al., 2008). Importantly, the wild-type
catalytically fragment of RanBP2 (RanBP2FG wt), but not
the catalytically inactive variant (RanBP2FG AA) restored
SUMO modification of Borealin (Figure 4A). Moreover,
when overexpressed, wild-type RanBP2FG, but not the in-
active mutant, lead to a dramatic defect in chromosome
segregation after anaphase onset (Figure 4, B–E).
Together, these data show that RanBP2 is essential for
SUMO modification of Borealin and suggest that unbal-
anced RanBP2-mediated SUMO conjugation prevents the
equal distribution of genetic material to daughter cells.
The critical role of RanBP2 in mitosis is further supported by
the observation that its protein level is strongly elevated
upon onset of mitosis (Figure 4F). This effect is due to
posttranscriptional regulation, because the mRNA level of
RanBP2 does not significantly change during cell cycle pro-
gression (Figure 4G).
It has been reported very recently that RanBP2-mediated
SUMO modification of topoisomerase II is required for its
localization to centromeres (Dawlaty et al., 2008). Notably,
depletion of RanBP2 or Ubc9 did not affect the centromeric
localization of Borealin (Figure 5A; data not shown), indi-
cating that centromere targeting of the CPC occurs indepen-
dently of Borealin sumoylation. To rule out that this result is
due to residual amounts of RanBP2 (or Ubc9) left after
corresponding siRNA treatment, we created a nonsumoylat-
able variant of Borealin. Because we were unable to assign
one or several specific lysine residues of Borealin as attach-
ment sites for SUMO, we had to mutate all its 25 lysine
residues to arginine to abolish sumoylation (Supplemental
Figure 4, A–D). During mitosis, HA-Borealin25KR exhibits
wild-type localization to the centromere, rescued the phos-
phorylation of the Aurora B substrate CENP-A and bound to
the central spindle in anaphase cells (Figure 5B). In line with
the notion that the CPC requires the Borealin subunit to
target to its distinct locations (Klein et al., 2006, Jeyaprakash
et al., 2007) HA-Borealin25KR associated with all other CPC
components (Figure 5C). Interestingly, this mutant fails to
exhibit normal localization to the nucleolus in interphase
cells depleted from endogenous Borealin (Supplemental Fig-
ure 4E). However, this effect is unlikely due to the loss of
SUMO modification, because the general inhibition of
sumoylation did not affect the nucleolar localization of wild-
type Borealin (Supplemental Figure 4F).
These data suggest that complex formation of the CPC
and localization of the complex to the centromere and cen-
tral spindle during mitosis occur independently of sumo-
ylation. Consistent with this idea, general abrogation of
SUMO2/3 conjugation by expression of SENP2 (Zhang et al.,
2008) did not affect localization of Borealin and CPC activity
(Supplemental Figure 5, A and B).
SENP3 Catalyzes Desumoylation of Borealin
We next asked whether one of the known SUMO-specific
isopeptidases might be involved in the desumoylation of
Borealin. Thus, we first searched for a physical interaction of
Borealin with members of the human SENP family (SENP1,
SENP2, SENP3, or SENP5) in the yeast two-hybrid system.
Among the tested candidates, only SENP3 showed binding
to Borealin in this experimental system (Supplemental Fig-
ure 2B). This finding was corroborated by coimmunoprecip-
tation experiments in mammalian cells using FLAG-tagged
SENP3 and myc-tagged constructs of Borealin. Full-length
Figure 4. RanBP2FG restores sumoylation of Borealin in RanBP2
depleted cells. (A) FLAG-tagged Borealin and His-SUMO2 were
coexpressed in HeLa cells treated with siRNA oligonucleotides
directed against RanBP2 or GL2 as control. In parallel, cells were
transfected with either empty myc-vector (), myc-tagged wild-
type RanBP2FG (wt) or catalytically inactive RanBP2FG (AA) bear-
ing the mutations L2651A and L2653A. Depletion of RanBP2 and
expression of myc-tagged RanBP2FG constructs was verified by
Western blotting. His-SUMO2 conjugates were recovered on Ni-
NTA beads, and Western blotting was performed with anti-FLAG
antibodies to detect Borealin-SUMO conjugates. (B–E) Overexpres-
sion of RanBP2FG causes chromosome missegregation during mi-
tosis. (B) Untransfected mitotic control cells stained with Borealin
antibodies. (C) HeLa cells were transfected with myc-tagged
RanBP2FG and stained with myc- and Borealin antibodies. Note the
massive chromosome missegregation after anaphase onset. (D) Ex-
periment as in C. Bottom, costaining of myc- and tubulin antibodies.
(E) Experiment as in C, but the catalytically inactive RanBP2FG con-
struct (RanBP2FG AA) was transfected. DNA was stained with 4,6-
diamidino-2-phenylindole (DAPI). Bar, 10 m. (F) RanBP2 protein
level at distinct cell cycle stages. HeLa cells were released from a
double thymidine block into nocodazole, and lysates were prepared
at different time points after nocodazole release and detected by
anti-RanBP2 antibodies. The mitotic status was assayed by moni-
toring Cyclin B1 levels. Tubulin protein level serves as a loading
control. as.  asynchronous growing cells. (G) RanBP2 and Borealin
mRNA levels upon cell cycle progression were determined in syn-
chronized HeLa cells by using quantitative RT-PCR.
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Borealin as well as an N-terminal fragment of Borealin
(Borealin1-140) coprecipitated SENP3, whereas no interaction
was detected between SENP3 and the C-terminal fragment
of Borealin (Borealin141-280) (Figure 6A). Consistent with this
finding and previously reported data on their subcellular
distribution (Nishida et al., 2000; Gassmann et al., 2004),
FLAG-SENP3 and HA-Borealin exhibit colocalization in the
nucleolus in interphase cells (Figure 6B). In early mitosis,
after nucleolar disassembly SENP3 is found evenly distrib-
uted in the cytosol, thus showing partial overlap with Bo-
realin (Figure 6C). In late mitosis, it accumulates at the
reforming nuclear envelope and reenters the nucleolus dur-
ing cytokinesis (Figure 6C). Noteworthy, the overexpres-
sion of FLAG-SENP3 did not affect the normal localization of
endogenous Borealin in distinct mitotic stages. Importantly,
SENP3 is heavily phosphorylated in cells that were arrested
in early mitosis by treatment with nocodazole (Supplemen-
tal Figure 6).
To directly analyze whether SENP3 can catalyze de-
sumoylation of Borealin, an in vitro demodification assay
was performed. Borealin, premodified by either SUMO1 or
SUMO2, was incubated with wild-type or catalytically
inactive mutant forms of either SENP3 or SENP5, the
closest homologue of SENP3 in humans. Although Borealin-
SUMO1 conjugates were not influenced by the addition of
either SENP (Figure 7A, lanes 3–6), the amount of Borealin–
SUMO2 conjugates was greatly reduced in reactions supple-
mented with the wild-type SENP3 protein, but it was unaf-
fected by the inactive protein (Figure 7A, compare lanes 8
and 9). In comparison, SENP5 only marginally reduced the
amount of Borealin–SUMO2 conjugates (Figure 6A, lane 10).
Noteworthy, however, SENP5 used in these assays is enzy-
matically active as demonstrated by its ability to catalyze
C-terminal processing of the SUMO2 precursor (Supplemen-
tal Figure 7).
Next, we assessed SENP3-catalyzed demodification of Bo-
realin in vivo. Confirming and extending the in vitro results,
expression of wild-type SENP3, but not the inactive mutant,
induced an almost complete loss of Borealin–SUMO2 con-
jugates (Figure 7B, compare lane 11 and 12), whereas the
level of Borealin–SUMO1 species was not affected (Figure
7A, lanes 8 and 9). To further study the involvement of
endogenous SENP3 in desumoylation of Borealin, His-Bo-
realin was expressed in HeLa cells and SENP3 was depleted
from cells by siRNA duplexes. Efficient down-regulation of
the protein was verified by immunoblotting with an anti-
SENP3 antibody (Figure 7C). Importantly, upon depletion
of SENP3 the amount of Borealin–SUMO2/3 conjugates was
significantly increased. Noteworthy, depletion of SENP5 did
not affect Borealin-SUMO2/3 conjugates, whereas depletion
of RanBP2 reduced the amount of sumoylated Borealin (Fig-
ure 7C).
Figure 5. CPC assembly and localization to the centromere and
central spindle are independent of Borealin sumoylation. (A)
RanBP2 does not influence CPC localization to the kinetochore/
centromere region and vice versa. HeLa cells were treated with
indicated siRNA duplexes for 48 h and stained for RanBP2 and
Borealin. DNA was stained with DAPI. Bar, 10 m. (B) HeLa cells
were treated with siRNA duplexes specific for the 3 untranslated
region of Borealin and simultaneously transfected with HA-Bo-
realin or HA-Borealin25KR. Immunofluorescence was performed
with antibodies directed against HA, phospho(S7)-CENP-A, and
PRC1. DNA was stained with DAPI. Bar, 10 m. (C) HeLa cells
were transfected with the indicated constructs, arrested in S
phase by thymidine treatment, and released for 10 h to enter
mitosis. Mitotic lysates were prepared and immunoprecipitations
were performed with anti-HA antibodies and probed by Western
blotting with the indicated antibodies. Asterisk denotes immu-
noglobulin heavy chain.
Figure 6. SENP3 colocalizes and interacts with Borealin. (A) FLAG-
tagged SENP3 and myc-tagged constructs of Borealin were coex-
pressed in HeLa cells. Immunoprecipitations were performed using
anti-myc antibodies. The two fragments of Borealin show a different
electrophoretic mobility due to different isoelectric points. Asterisks
denote immunoglobulins. (B) SENP3 and Borealin colocalize in
interphase nucleoli. HeLa cells were transfected with FLAG-SENP3
and HA-Borealin. Localization was determined by immunostaining
with anti-HA and anti-FLAG antibodies. (C) Localization of SENP3
during mitosis. HeLa cells were transfected with FLAG-tagged
SENP3 and incubated for 48 h. Immunostaining was performed
with anti-FLAG and anti-Borealin antibodies. SENP3 localizes to the
cytoplasm during mitosis and showed partial overlap with Borealin
from prophase until anaphase. (C) During telophase SENP3 accu-
mulates at the reforming nuclear envelope and reenters the nucle-
olus during cytokinesis. DNA was stained with DAPI. Bar, 10 m.
SUMO 2/3 Conjugation-Deconjugation of Borealin
Vol. 20, January 1, 2009 415
Together, these data strongly indicate that SENP3 exerts
protease activity on Borealin and specifically reverts the
modification of Borealin by SUMO2/3.
DISCUSSION
The data reported here define a mitotic pathway of
SUMO2/3 conjugation–deconjugation on the CPC compo-
nent Borealin. Importantly, this pathway is controlled by the
E3 SUMO ligase RanBP2 and the SUMO-specific isopepti-
dase SENP3. Modification of Borealin occurs at up to three
lysine residues, but by individual or combinatorial muta-
tions of a series of lysine residues we were unable to assign
distinct residues for attachment of SUMO. This scenario may
be explained by the fact that none of the 25 lysine residues of
Borealin is embedded in a KxE/D motif, which serves as
preferential SUMO attachment sites in the majority of
SUMO substrates (also see Supplemental Figure 5D). Due to
the difficulties in obtaining a SUMO-deficient version of
Borealin by mutating distinct lysine residues, we had to
generate a lysine-less version of Borealin to abolish sumo-
ylation. Notably, however, this mutant does show sumo-
ylation-independent defects, such as impaired nucleolar
localization in interphase (Supplemental Figure 4E). This
complicates its further use in complementation experiments
because it would be difficult to directly link functional dif-
ferences between Borealin25KR and wild-type Borealin to a
loss of sumoylation rather than the loss of other modifica-
tions at these residues or structural alterations.
Interestingly, recent work in yeast described sumoylation
of Bir1, the yeast relative of Survivin (Montpetit et al., 2006).
We show that Survivin is not a major target of SUMO
modification in human cells. Notably, however, yeast lacks a
Borealin homologue, and it has been proposed that the
functions of human Survivin and Borealin are combined in
the single yeast Bir1 protein (Vader et al., 2006). Therefore,
these data support the idea that sumoylation of the CPC is
an evolutionary conserved mechanism. However, the func-
tional impact of SUMO on CPC activity in both lower and
higher eukaryotes remains to be elucidated.
An exciting new aspect in the SUMO/ubiquitin field is the
emerging interplay of both modification systems on a given
target protein. Interestingly, recent work has shown that a
balanced nondegradative ubiquitination–deubiquitination
cycle of Survivin is required for the chromosome segrega-
tion function of the CPC at the centromere (Vong et al., 2005).
Modification of Borealin and Survivin by SUMO and ubiq-
uitin, respectively, thus provides an example, where both
modification systems target distinct components of a multi-
protein complex.
Borealin–SUMO2/3 conjugates are most prominent in
early mitosis when the CPC is associated with the centro-
mere, suggesting that the SUMO-modified fraction of Borea-
lin is associated with these structures. This would be in line
with observations from Xenopus egg extracts and human
cells, which show that during prometaphase/metaphase
SUMO2/3 is found at centromeres and chromatin, whereas
SUMO1 localizes to the mitotic spindle and the spindle
midzone (Azuma et al., 2003; Ayaydin and Dasso, 2004;
Zhang et al., 2008). The loss of Borealin sumoylation ob-
served during later mitotic phases (around anaphase onset)
when the CPC translocates to the central spindle is in agree-
ment with SUMO2/3 being chromatin associated also dur-
ing these stages (Zhang et al., 2008). The importance of
SUMO function at the kinetochore/centromere is under-
scored by the recent finding that overexpression of SENP2 in
HeLa cells leads to a loss of SUMO2/3 from these structures
and induces a prometaphase-like arrest due to a failure in
kinetochore targeting of the microtubule motor CENP-E
(Zhang et al., 2008; Supplemental Figure 6B).
Figure 7. SENP3 catalyzes desumoylation of Borealin. (A) FLAG-
tagged versions of wild-type SENP3 (SENP3wt, lanes 3 and 8) and
SENP5 (SENP5wt, lanes 5 and 10), or the catalytically inactive mu-
tants (SENP3C532S, lanes 4 and 9, and SENP5C713S, lanes 6 and 11),
generated by in vitro translation/transcription, were added to in
vitro sumoylated Borealin. The anti-FLAG Western blot serves as a
loading control for the proteases. Note deconjugation of SUMO2/3,
but not SUMO1, of Borealin when incubated with SENP3wt but not
SENP3C532S. (B) Myc-tagged Borealin and His-SUMO constructs
were coexpressed with FLAG-tagged SENP3wt (lanes 2, 5, 8, and 11)
or SENP3C532S (lanes 3, 6, 9, and 12) in HeLa cells. His-SUMO
conjugates were recovered on Ni-NTA beads (lanes 7–12), and
Western blotting was performed with anti-myc antibodies. Expres-
sion of SENP3 constructs was verified by anti-FLAG Western blot-
ting. (C and C) SENP3 depletion leads to accumulation of
SUMO2/3 modified Borealin. HeLa cells were transfected with
His-tagged Borealin and indicated siRNA duplexes, arrested in S
phase by thymidine treatment, and released for 10 h to enter mito-
sis. Mitotic lysates were prepared and Ni-NTA precipitation was
performed as described above. Immunoblotting was performed
with indicated antibodies to demonstrate depletion of correspond-
ing proteins (C) and monitor the sumoylation status of Borealin (C).
The Borealin reactive bands at 45 kDa (asterisk in C) is interpreted
as a Borealin–SUMO2/3 degradation product. Note that knock-
down of SENP3, but not SENP5, enhances Borealin sumoylation
compared with control-depleted cells. In contrast, RanBP2 knock-
down results in a loss of Borealin modification.
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We could assign the centromere/kinetochore protein Bo-
realin as a physiological target for RanBP2-mediated sumo-
ylation. RanBP2 is found at the nuclear pore in interphase
cells, but it redistributes to the mitotic spindle and the
kinetochore/centromere upon entry of cells into mitosis
(Yokoyama et al., 1995; Joseph et al., 2002, 2004). Similarly to
what was shown for topoisomerase II (Dawlaty et al., 2008),
we found that RanBP2 associates with the CPC in mitosis,
stimulates SUMO modification of Borealin in vitro, and is
essential for Borealin sumoylation in vivo. Interestingly, we
observe a drastic defect in chromosome segregation upon
ectopic overexpression of the catalytically fragment of
RanBP2. However, in contrast to what was observed for
topoisomerase II, sumoylation of Borealin does not seem to
be required for centromere targeting of the CPC. In line with
this observation, CPC components are still present at cen-
tromeres in cells overexpressing SENP2 (Zhang et al., 2008;
Supplemental Figure 6A). Interestingly, as demonstrated for
CENP-E, dynamic association of centromeric proteins to
these structures also involves noncovalent interactions be-
tween a SUMO-modified acceptor protein and a specific
binding partner, which harbors a SUMO interaction motif
(SIM) (Zhang et al., 2008). Thus, one may envision that the
attachment of the SUMO moiety to Borealin may provide a
centromeric docking site for a yet to be identified SIM-
containing binding partner. Indeed, it was shown that the
CPC constitutes one of the most upstream components of
centromere/kinetochore assembly (Vigneron et al., 2004; Liu
et al., 2006; Emanuele et al., 2008).
The dynamics of sumoylation are controlled by SUMO
isopeptidases and the importance of SUMO deconjugation is
illustrated by genetic data from yeast and mice showing that
like conjugation, deconjugation is needed for viability. In
yeast, Ulp1 has an essential role in the G2/M phase of the
cell cycle, whereas Ulp2, which seems to be particularly
important for the depolymerization of SUMO chains, is in-
volved in the control of chromosome cohesion at centro-
meric regions (Li and Hochstrasser, 1999; Li and Hoch-
strasser, 2000 Bachant et al., 2002). In mammalian cells
depletion of SENP5, the closest homologue of SENP3 in
humans causes a cytokinesis defect, indicating that SENP5
functions in mitosis (Di Bacco et al., 2006). Noteworthy,
however, depletion of SENP5 did not affect Borealin–
SUMO2/3 conjugates and did not interfere with CPC local-
ization or function (our unpublished observation), indicat-
ing that the defect in cytokinesis is not related to an altered
CPC function. Accordingly, SENP5 did not bind to Borealin
and exhibited only a low catalytic activity toward Borealin–
SUMO2/3 conjugates in vitro. By contrast, we identified
SENP3 as a specific interaction partner of Borealin and
showed that SENP3 catalyzes the removal of SUMO2/3
from Borealin both in vitro and in vivo. Thus, SENP3 fea-
tures an activity that catalyzes desumoylation of Borealin
in mitosis. The preferential activity of SENP3 toward
SUMO2/3 conjugates confirms previous reports (Nishida et
al., 2000; Gong and Yeh, 2006; Haindl et al., 2008) and
strengthens the concept of a functional divergence of distinct
SUMO forms in mitosis. In interphase cells, SENP3 is found
in the nucleolus, where it functions as an essential factor of
ribosome biogenesis (Haindl et al., 2008), but little is known
about SENP3 function during mitosis. SENP3 was recently
identified in an siRNA screen as a potential component of
the spindle assembly checkpoint (SAC) (Stegmeier et al.,
2007), but depletion of SENP3 did not interfere with CPC
targeting to the centromere or activity of the CPC at these
sites (our unpublished observation), suggesting that SENP3
affects SAC function downstream of CPC recruitment to the
centromere. Interestingly, SENP3 is phosphorylated in mi-
tosis, suggesting that its activity and/or localization are
controlled by mitotic kinases. Recent proteomic studies in-
deed found SENP3, and in particular a phosphorylated form
of SENP3, at the mitotic spindle (Sauer et al., 2005; Nousi-
ainen et al., 2006). This indicates that at least a subfraction of
the protease acts on spindle associated components, which is
consistent with the loss of Borealin sumoylation in ana-
phase, when the CPC is transferred to the mitotic spindle.
In summary our data indicate that in addition to its role in
ribosome biogenesis SENP3 exhibits an important mitotic
function. Because cell cycle progression and ribosome bio-
genesis are tightly interconnected (Dez and Tollervey, 2004),
SENP3 may represent a critical factor that coordinates both
processes. Identification of novel SENP3 targets may thus
shed more light on the question of how the SUMO system
regulates key mitotic processes.
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